Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Allogene Therapeutics says FDA lifts hold on clinical trials » 16:33
01/10/22
01/10
16:33
01/10/22
16:33
ALLO

Allogene Therapeutics

$12.20 /

-1.255 (-9.33%)

, CLLS

Cellectis

$7.91 /

+0.175 (+2.26%)

Cellectis (CLLS) stated…

Cellectis (CLLS) stated that its licensed partner, Allogene Therapeutics (ALLO) announced that the U.S. FDA has lifted the hold on its clinical trials. The FDA had placed a clinical hold on all five of Allogene's clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene's ALPHA2 study. Allogene reported that the investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogene's manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the natural T cell or B cell maturation process. Allogene also announced that following the lift of the clinical holds and pending final discussions with the FDA, Allogene intends to initiate a Phase 2 pivotal trial of ALLO-501A in relapsed/refractory large B-cell lymphoma mid-year 2022. Allogene's allogeneic CAR-T programs utilize Cellectis' technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. Allogene has an exclusive license to Cellectis' technologies for ALLO-715, ALLO-605 (both directed at BCMA) and ALLO-316 (directed at CD70) and holds development and commercial rights for these investigational product candidates.

ShowHide Related Items >><<
CLLS Cellectis
$7.91 /

+0.175 (+2.26%)

ALLO Allogene Therapeutics
$12.20 /

-1.255 (-9.33%)

ALLO Allogene Therapeutics
$12.20 /

-1.255 (-9.33%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
CLLS Cellectis
$7.91 /

+0.175 (+2.26%)

01/06/22 Wells Fargo
Cellectis downgraded to Equal Weight from Overweight at Wells Fargo
11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
CLLS Cellectis
$7.91 /

+0.175 (+2.26%)

ALLO Allogene Therapeutics
$12.20 /

-1.255 (-9.33%)

ALLO Allogene Therapeutics
$12.20 /

-1.255 (-9.33%)

ALLO Allogene Therapeutics
$12.20 /

-1.255 (-9.33%)

Downgrade
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16 » 07:06
01/06/22
01/06
07:06
01/06/22
07:06
CLLS

Cellectis

$7.81 /

-0.48 (-5.79%)

, ALLO

Allogene Therapeutics

$13.75 /

-0.76 (-5.24%)

As previously reported,…

As previously reported, Wells Fargo analyst Nick Abbott downgraded Cellectis (CLLS) to Equal Weight from Overweight with a price target of $16, down from $39, considering extended timelines for off-the-shelf allogeneic CAR-T development, increasing competition from and to off-the-shelf cell therapy, selection of challenging indications, concern over the longer term ramifications from the allogeneic CAR-T clinical hold for Cellectis technology licensee Allogene (ALLO) and updated valuation of CALYXT ownership. The analyst also notes that Cellectis did not provide 2022 guidance for in-vivo gene therapy product, TALGlobin-01 for sickle cell disease. With delay in Allogene clinical programs, Abbott is assuming a delay in collaboration revenues.

ShowHide Related Items >><<
CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

ALLO Allogene Therapeutics
$13.75 /

-0.76 (-5.24%)

CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

01/06/22 Wells Fargo
Cellectis downgraded to Equal Weight from Overweight at Wells Fargo
11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
ALLO Allogene Therapeutics
$13.75 /

-0.76 (-5.24%)

01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
12/14/21 RBC Capital
Allogene Therapeutics price target lowered to $35 from $45 at RBC Capital
12/13/21 Cowen
Allogene Therapeutics named a best idea for 2022 at Cowen
CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

ALLO Allogene Therapeutics
$13.75 /

-0.76 (-5.24%)

ALLO Allogene Therapeutics
$13.75 /

-0.76 (-5.24%)

ALLO Allogene Therapeutics
$13.75 /

-0.76 (-5.24%)

Downgrade
Cellectis downgraded to Equal Weight from Overweight at Wells Fargo » 05:19
01/06/22
01/06
05:19
01/06/22
05:19
CLLS

Cellectis

$7.81 /

-0.48 (-5.79%)

Wells Fargo analyst Nick…

Wells Fargo analyst Nick Abbott downgraded Cellectis to Equal Weight from Overweight with a $16 price target.

ShowHide Related Items >><<
CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
CLLS Cellectis
$7.81 /

-0.48 (-5.79%)

Over a month ago
Conference/Events
Cellectis management to meet virtually with Oppenheimer. » 04:55
12/17/21
12/17
04:55
12/17/21
04:55
CLLS

Cellectis

$8.24 /

-0.165 (-1.96%)

Virtual Meetings to be…

Virtual Meetings to be held December 16-17 hosted by Oppenheimer.

ShowHide Related Items >><<
CLLS Cellectis
$8.24 /

-0.165 (-1.96%)

CLLS Cellectis
$8.24 /

-0.165 (-1.96%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
CLLS Cellectis
$8.24 /

-0.165 (-1.96%)

Conference/Events
Cellectis management to meet virtually with Oppenheimer. » 09:47
12/16/21
12/16
09:47
12/16/21
09:47
CLLS

Cellectis

$8.41 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held December 16-17 hosted by Oppenheimer.

ShowHide Related Items >><<
CLLS Cellectis
$8.41 /

+ (+0.00%)

CLLS Cellectis
$8.41 /

+ (+0.00%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
CLLS Cellectis
$8.41 /

+ (+0.00%)

Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 04:55
12/14/21
12/14
04:55
12/14/21
04:55
ABBV

AbbVie

$126.50 /

+1.035 (+0.82%)

, AGIO

Agios Pharmaceuticals

$31.66 /

+2.09 (+7.07%)

, CLLS

Cellectis

$8.41 /

-0.04 (-0.47%)

, EXAS

Exact Sciences

$78.10 /

-1.24 (-1.56%)

, EDIT

Editas Medicine

$29.28 /

+0.3 (+1.04%)

, BEAM

Beam Therapeutics

$76.94 /

+3.22 (+4.37%)

, AZN

AstraZeneca

$54.59 /

+0.58 (+1.07%)

, CYAD

Celyad

$4.43 /

+0.01 (+0.23%)

, GMAB

Genmab

$38.02 /

-0.005 (-0.01%)

, VIRX

Viracta Therapeutics

$3.82 /

-0.375 (-8.95%)

, TGTX

TG Therapeutics

$16.09 /

-0.48 (-2.90%)

, MBRX

Moleculin Biotech

$2.18 /

-0.135 (-5.84%)

, MBIO

Mustang Bio

$1.82 /

-0.245 (-11.86%)

, XNCR

Xencor

$33.87 /

+0.17 (+0.50%)

, SANA

Sana Biotechnology

$18.27 /

+0.665 (+3.78%)

, KPTI

Karyopharm

$6.03 /

+0.04 (+0.67%)

, GILD

Gilead

$69.90 /

+0.37 (+0.53%)

, DTIL

Precision BioSciences

$8.20 /

-0.39 (-4.54%)

, INCY

Incyte

$67.79 /

+2.51 (+3.84%)

, IMRA

Imara

$2.78 /

-0.04 (-1.42%)

, REGN

Regeneron

$660.15 /

-9.34 (-1.40%)

, MOR

MorphoSys

$9.19 /

-0.17 (-1.82%)

, NVS

Novartis

$80.83 /

+0.125 (+0.15%)

, BMY

Bristol-Myers

$59.05 /

+2.7 (+4.79%)

, FATE

Fate Therapeutics

$48.93 /

-0.24 (-0.49%)

, PFE

Pfizer

$55.23 /

+2.43 (+4.60%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GMAB Genmab
$38.02 /

-0.005 (-0.01%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

CYAD Celyad
$4.43 /

+0.01 (+0.23%)

CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

12/13/21 Cowen
Agios Pharmaceuticals named a best idea for 2022 at Cowen
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
CYAD Celyad
$4.43 /

+0.01 (+0.23%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-0.005 (-0.01%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$69.90 /

+0.37 (+0.53%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
INCY Incyte
$67.79 /

+2.51 (+3.84%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.78 /

-0.04 (-1.42%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$660.15 /

-9.34 (-1.40%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.83 /

+0.125 (+0.15%)

12/13/21 Credit Suisse
Novartis price target lowered to CHF 85 from CHF 90 at Credit Suisse
12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

12/13/21 Alliance Global Partners
Gamida Cell data at ASH meeting 'encouraging,' says Alliance Global Partners
12/13/21 Oppenheimer
Fate lymphoma update should erase concerns, says Oppenheimer
12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
PFE Pfizer
$55.23 /

+2.43 (+4.60%)

12/13/21
Fly Intel: Top five analyst upgrades
12/13/21 Citi
Arena 'highly attractive' for Pfizer, but FTC a concern, says Citi
12/13/21 Piper Sandler
Piper keeps $50 target on Ventyx after Pfizer buys Arena
12/13/21 UBS
Pfizer upgraded to Buy from Neutral at UBS
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

XNCR Xencor
$33.87 /

+0.17 (+0.50%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GMAB Genmab
$38.02 /

-0.005 (-0.01%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 04:55
12/13/21
12/13
04:55
12/13/21
04:55
ABBV

AbbVie

$125.46 /

+1.325 (+1.07%)

, AGIO

Agios Pharmaceuticals

$29.57 /

-0.99 (-3.24%)

, CLLS

Cellectis

$8.45 /

-0.26 (-2.99%)

, EXAS

Exact Sciences

$79.28 /

-1.82 (-2.24%)

, EDIT

Editas Medicine

$29.03 /

-1.48 (-4.85%)

, BEAM

Beam Therapeutics

$73.72 /

+0.22 (+0.30%)

, AZN

AstraZeneca

$54.01 /

-0.96 (-1.75%)

, CYAD

Celyad

$4.42 /

-0.59 (-11.78%)

, GMAB

Genmab

$38.02 /

-1.44 (-3.65%)

, VIRX

Viracta Therapeutics

$4.21 /

+0.01 (+0.24%)

, TGTX

TG Therapeutics

$16.57 /

-0.1 (-0.60%)

, MBRX

Moleculin Biotech

$2.33 /

+0.155 (+7.13%)

, MBIO

Mustang Bio

$2.07 /

-0.025 (-1.20%)

, XNCR

Xencor

$33.81 /

-0.36 (-1.05%)

, SANA

Sana Biotechnology

$17.61 /

-0.315 (-1.76%)

, KPTI

Karyopharm

$5.99 /

-0.47 (-7.28%)

, GILD

Gilead

$70.24 /

-0.06 (-0.09%)

, DTIL

Precision BioSciences

$8.59 /

-0.28 (-3.16%)

, INCY

Incyte

$65.39 /

-1.05 (-1.58%)

, IMRA

Imara

$2.84 /

-0.14 (-4.70%)

, REGN

Regeneron

$669.12 /

+3.38 (+0.51%)

, MOR

MorphoSys

$9.36 /

-0.44 (-4.49%)

, NVS

Novartis

$80.71 /

+0.255 (+0.32%)

, BMY

Bristol-Myers

$56.35 /

-1.21 (-2.10%)

, FATE

Fate Therapeutics

$49.17 /

-4.04 (-7.59%)

, PFE

Pfizer

$52.80 /

+0.705 (+1.35%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CYAD Celyad
$4.42 /

-0.59 (-11.78%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 H.C. Wainwright
Agios Pharmaceuticals price target raised to $93 from $88 at H.C. Wainwright
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
CYAD Celyad
$4.42 /

-0.59 (-11.78%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-1.44 (-3.65%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$70.24 /

-0.06 (-0.09%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
INCY Incyte
$65.39 /

-1.05 (-1.58%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.84 /

-0.14 (-4.70%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.71 /

+0.255 (+0.32%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
11/08/21 Citi
Fate Therapeutics upgraded to Buy from Neutral at Citi
11/05/21 Roth Capital
Fate Therapeutics price target lowered to $60 from $90 at Roth Capital
PFE Pfizer
$52.80 /

+0.705 (+1.35%)

12/10/21 Barclays
Pfizer price target raised to $54 from $44 at Barclays
12/09/21
Fly Intel: Top five analyst upgrades
12/09/21 Erste Group
Pfizer upgraded to Buy from Hold at Erste Group
12/08/21 Wells Fargo
Pfizer initiated with an Overweight at Wells Fargo
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

XNCR Xencor
$33.81 /

-0.36 (-1.05%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

Hot Stocks
Cellectis reports data from BALLI-01 study, preclinical data from TALGlobin01 » 16:07
12/12/21
12/12
16:07
12/12/21
16:07
CLLS

Cellectis

$8.45 /

-0.26 (-2.99%)

Cellectis announced…

Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients at the 63rd Annual Meeting of the American Society of Hematology in Atlanta, Georgia. BALLI-01, a phase 1 open-label dose-escalation study, is designed to assess the safety, maximum tolerated dose, and preliminary anti-leukemia activity of UCART22 in patients with r/r B-ALL. Additional endpoints include characterization of the expansion, trafficking, and persistence of UCART22 cells. As of the clinical cut-off date of October 1, 2021, 12 patients received lymphodepletion; 11 were administered UCART22, of which 6 received UCART22 and FCA. Enrolled patients were predominantly male, young, and most had recurrent genetic abnormalities including the CRFL2 rearrangement. Additionally, enrolled patients were heavily pretreated with a median of 3 prior lines of therapy. Three-fourths of patients had received prior blinatumomab, approximately half had received prior inotuzumab, and 3 had received prior CD19 autologous CAR-T therapy. The FCA lymphodepletion regimen was well tolerated, and most treatment-emergent adverse events were mild to moderate in intensity and manageable. Importantly, no patients experienced protocol-defined dose limiting toxicities, immune effector cell-associated neurotoxicity syndrome, nor UCART22-related severe TEAEs. Three patients experienced mild to moderate cytokine release syndrome, and one patient reported grade II GvHD with skin involvement only, that required hospitalization. The company also said that "encouraging" anti-leukemic activity was observed in two patients in the FCA cohorts. Both patients, one at DL2 and one at DL2i, achieved blast reductions to less than 5% by day 28, accompanied by measurable UCART22 expansion and changes in relevant inflammatory cytokines. Overall, UCART22 after FCA lymphodepletion regimen demonstrated promising signs of anti-leukemic activity at DL2 and DL2i, without unexpected or significant treatment-related toxicity. The addition of alemtuzumab to the FC lymphodepletion regimen was safe and promoted sustained host T-cell suppression and expansion of UCART22. These data are encouraging and support the further development of UCART22 for patients with r/r B- ALL. BALLI-01 is currently enrolling patients at dose level 3 with FCA lymphodepletion. Initial pre-clinical data from Cellectis' .HEAL platform's product candidate, TALGlobin01 demonstrates that TALEN is specific and efficient in correcting the mutated beta-globin gene, the underlying cause of sickle cell disease. The data, presented in a poster, demonstrate that TALEN-based engineering could be used to correct the beta-globin gene mutation in HbSS patient-derived hematopoietic stem and progenitor cells. The data show up to 70% of HBB allelic correction, with only 9% of HBB biallelic inactivation and a low level of TALEN off-target cleavage. Genetic correction of HBB translates into high level of hemoglobin A expression and reversion of the sickling phenotype in differentiated red blood cells. Preclinical data show the capacity of TALGlobin01 edited cells to engraft in vivo using an NSG mouse model. Collectively, the preclinical data demonstrate high efficiency and safety of TALEN treatment in HbSS patient-derived hematopoietic stem and progenitor cells.

ShowHide Related Items >><<
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

  • 16
    Dec
Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 14:45
12/12/21
12/12
14:45
12/12/21
14:45
ABBV

AbbVie

$125.46 /

+1.325 (+1.07%)

, AGIO

Agios Pharmaceuticals

$29.57 /

-0.99 (-3.24%)

, CLLS

Cellectis

$8.45 /

-0.26 (-2.99%)

, EXAS

Exact Sciences

$79.28 /

-1.82 (-2.24%)

, EDIT

Editas Medicine

$29.03 /

-1.48 (-4.85%)

, BEAM

Beam Therapeutics

$73.72 /

+0.22 (+0.30%)

, AZN

AstraZeneca

$54.01 /

-0.96 (-1.75%)

, CYAD

Celyad

$4.42 /

-0.59 (-11.78%)

, GMAB

Genmab

$38.02 /

-1.44 (-3.65%)

, VIRX

Viracta Therapeutics

$4.21 /

+0.01 (+0.24%)

, TGTX

TG Therapeutics

$16.57 /

-0.1 (-0.60%)

, MBRX

Moleculin Biotech

$2.33 /

+0.155 (+7.13%)

, MBIO

Mustang Bio

$2.07 /

-0.025 (-1.20%)

, XNCR

Xencor

$33.81 /

-0.36 (-1.05%)

, SANA

Sana Biotechnology

$17.61 /

-0.315 (-1.76%)

, KPTI

Karyopharm

$5.99 /

-0.47 (-7.28%)

, GILD

Gilead

$70.24 /

-0.06 (-0.09%)

, DTIL

Precision BioSciences

$8.59 /

-0.28 (-3.16%)

, INCY

Incyte

$65.39 /

-1.05 (-1.58%)

, IMRA

Imara

$2.84 /

-0.14 (-4.70%)

, REGN

Regeneron

$669.12 /

+3.38 (+0.51%)

, MOR

MorphoSys

$9.36 /

-0.44 (-4.49%)

, NVS

Novartis

$80.71 /

+0.255 (+0.32%)

, BMY

Bristol-Myers

$56.35 /

-1.21 (-2.10%)

, FATE

Fate Therapeutics

$49.17 /

-4.04 (-7.59%)

, PFE

Pfizer

$52.80 /

+0.705 (+1.35%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CYAD Celyad
$4.42 /

-0.59 (-11.78%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 H.C. Wainwright
Agios Pharmaceuticals price target raised to $93 from $88 at H.C. Wainwright
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
CYAD Celyad
$4.42 /

-0.59 (-11.78%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-1.44 (-3.65%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$70.24 /

-0.06 (-0.09%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
INCY Incyte
$65.39 /

-1.05 (-1.58%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.84 /

-0.14 (-4.70%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.71 /

+0.255 (+0.32%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
11/08/21 Citi
Fate Therapeutics upgraded to Buy from Neutral at Citi
11/05/21 Roth Capital
Fate Therapeutics price target lowered to $60 from $90 at Roth Capital
PFE Pfizer
$52.80 /

+0.705 (+1.35%)

12/10/21 Barclays
Pfizer price target raised to $54 from $44 at Barclays
12/09/21
Fly Intel: Top five analyst upgrades
12/09/21 Erste Group
Pfizer upgraded to Buy from Hold at Erste Group
12/08/21 Wells Fargo
Pfizer initiated with an Overweight at Wells Fargo
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

XNCR Xencor
$33.81 /

-0.36 (-1.05%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

Conference/Events
JMP Securities to hold a virtual summit » 04:55
12/07/21
12/07
04:55
12/07/21
04:55
ALLO

Allogene Therapeutics

$17.19 /

-0.45 (-2.55%)

, BCYC

Bicycle Therapeutics

$50.35 /

-2.24 (-4.26%)

, BCAB

BioAtla

$22.46 /

+0.105 (+0.47%)

, BCRX

BioCryst

$11.18 /

-0.275 (-2.40%)

, BPMC

Blueprint Medicines

$95.36 /

+1.105 (+1.17%)

, CLLS

Cellectis

$8.08 /

-0.18 (-2.18%)

, CGEN

Compugen

$4.20 /

+0.03 (+0.72%)

, CTIC

CTI BioPharma

$1.68 /

+0.075 (+4.69%)

, CUE

Cue Biopharma

$10.94 /

-0.45 (-3.95%)

, CVAC

CureVac

$40.76 /

-2.91 (-6.66%)

, DCPH

Deciphera

$8.03 /

+0.03 (+0.38%)

, EFTR

eFfector Therapeutics

$7.44 /

+1.7 (+29.62%)

, GMDA

Gamida Cell

$2.34 /

-0.015 (-0.64%)

, HOOK

Hookipa Pharma

$2.94 /

+ (+0.00%)

, INBX

Inhibrx

$36.50 /

-0.49 (-1.32%)

, IOVA

Iovance Biotherapeutics

$16.93 /

+0.37 (+2.23%)

, KURA

Kura Oncology

$12.41 /

-0.05 (-0.40%)

, MGN

Mines Management

$1.13 /

+ (+0.00%)

, MOR

MorphoSys

$9.07 /

-0.39 (-4.12%)

, NXTC

NextCure

$5.84 /

+0.1 (+1.74%)

, PTGX

Protagonist Therapeutics

$32.77 /

+0.43 (+1.33%)

, PRTA

Prothena

$44.06 /

-2.565 (-5.50%)

, SPPI

Spectrum

$1.37 /

-0.005 (-0.36%)

, SYRS

Syros Pharmaceuticals

$3.96 /

+0.39 (+10.92%)

, VOR

Vor Biopharma

$13.15 /

+0.5 (+3.95%)

Hematology & Oncology…

Hematology & Oncology Virtual Summit to be held on December 6-7.Webcast Link

ShowHide Related Items >><<
VOR Vor Biopharma
$13.15 /

+0.5 (+3.95%)

SYRS Syros Pharmaceuticals
$3.96 /

+0.39 (+10.92%)

SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

PTGX Protagonist Therapeutics
$32.77 /

+0.43 (+1.33%)

PRTA Prothena
$44.06 /

-2.565 (-5.50%)

NXTC NextCure
$5.84 /

+0.1 (+1.74%)

MOR MorphoSys
$9.07 /

-0.39 (-4.12%)

KURA Kura Oncology
$12.41 /

-0.05 (-0.40%)

IOVA Iovance Biotherapeutics
$16.93 /

+0.37 (+2.23%)

INBX Inhibrx
$36.50 /

-0.49 (-1.32%)

HOOK Hookipa Pharma
$2.94 /

+ (+0.00%)

GMDA Gamida Cell
$2.34 /

-0.015 (-0.64%)

EFTR eFfector Therapeutics
$7.44 /

+1.7 (+29.62%)

DCPH Deciphera
$8.03 /

+0.03 (+0.38%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

CUE Cue Biopharma
$10.94 /

-0.45 (-3.95%)

CTIC CTI BioPharma
$1.68 /

+0.075 (+4.69%)

CLLS Cellectis
$8.08 /

-0.18 (-2.18%)

CGEN Compugen
$4.20 /

+0.03 (+0.72%)

BPMC Blueprint Medicines
$95.36 /

+1.105 (+1.17%)

BCYC Bicycle Therapeutics
$50.35 /

-2.24 (-4.26%)

BCRX BioCryst
$11.18 /

-0.275 (-2.40%)

ALLO Allogene Therapeutics
$17.19 /

-0.45 (-2.55%)

ALLO Allogene Therapeutics
$17.19 /

-0.45 (-2.55%)

12/03/21 Canaccord
Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord
10/19/21 Cowen
Allogene Therapeutics assumed with an Outperform at Cowen
10/12/21 JMP Securities
Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities
10/08/21
Fly Intel: Top five analyst downgrades
BCYC Bicycle Therapeutics
$50.35 /

-2.24 (-4.26%)

10/14/21 JMP Securities
Bicycle Therapeutics price target raised to $85 from $53 at JMP Securities
10/11/21 Canaccord
Bicycle Therapeutics price target raised to $60 from $40 at Canaccord
10/08/21 Oppenheimer
Bicycle Therapeutics price target raised to $65 from $47 at Oppenheimer
10/08/21 B. Riley
Bicycle Therapeutics price target raised to $72 from $56 at B. Riley
BCAB BioAtla
$22.46 /

+0.105 (+0.47%)

10/14/21 BTIG
BioAtla assumed with a Buy at BTIG
06/28/21 Roth Capital
BioAtla initiated with a Buy at Roth Capital
05/04/21 Credit Suisse
BioAtla assumed with an Outperform at Credit Suisse
05/04/21 JPMorgan
BioAtla price target raised to $64 from $45 at JPMorgan
BCRX BioCryst
$11.18 /

-0.275 (-2.40%)

11/22/21 Piper Sandler
BioCryst financing lifts one of two overhangs, says Piper Sandler
11/04/21 Barclays
BioCryst price target lowered to $17 from $21 at Barclays
11/03/21 Piper Sandler
BioCryst earnings pullback a buying opportunity, says Piper Sandler
08/06/21 Jefferies
BioCryst downgraded to Hold from Buy at Jefferies
BPMC Blueprint Medicines
$95.36 /

+1.105 (+1.17%)

12/01/21 Raymond James
Blueprint Medicines added to Analyst Current Favorites list at Raymond James
11/29/21 Stifel
Stifel expects neutral reaction for Blueprint acquisition of Lengo Therapeutics
11/29/21 Piper Sandler
Blueprint acquisition may surprise investors looking for buyout, says Piper
11/19/21 Morgan Stanley
Blueprint Medicines assumed with an Equal Weight at Morgan Stanley
CLLS Cellectis
$8.08 /

-0.18 (-2.18%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
CGEN Compugen
$4.20 /

+0.03 (+0.72%)

CTIC CTI BioPharma
$1.68 /

+0.075 (+4.69%)

12/01/21 Lake Street
CTI BioPharma delay creates buying opportunity, says Lake Street
10/04/21 Lake Street
CTI BioPharma should be bought on weakness after PRE-VENT miss, says Lake Street
08/09/21 BTIG
CTI BioPharma initiated with a Buy at BTIG
06/01/21 Lake Street
CTI BioPharma price target raised to $15 from $13 at Lake Street
CUE Cue Biopharma
$10.94 /

-0.45 (-3.95%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
CureVac initiated with a Hold at Deutsche Bank
07/01/21 Berenberg
CureVac COVID vaccine data may be enough for EU approval, says Berenberg
06/30/21
CureVac announces COVID vaccine candidate demonstrates 48% efficacy
DCPH Deciphera
$8.03 /

+0.03 (+0.38%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
EFTR eFfector Therapeutics
$7.44 /

+1.7 (+29.62%)

11/08/21 Stifel
eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism
11/08/21 Stifel
eFfector Therapeutics upgraded to Buy from Hold at Stifel
10/12/21 Credit Suisse
eFfector Therapeutics initiated with an Outperform at Credit Suisse
10/04/21 Mizuho
eFfector Therapeutics initiated with a Buy at Mizuho
GMDA Gamida Cell
$2.34 /

-0.015 (-0.64%)

11/16/21 H.C. Wainwright
Gamida Cell price target lowered to $22 from $27 at H.C. Wainwright
11/16/21 Oppenheimer
Gamida Cell price target lowered to $15 from $17 at Oppenheimer
11/15/21 Piper Sandler
Gamida Cell price target lowered to $13 from $23 at Piper Sandler
11/01/21 Alliance Global Partners
Gamida Cell initiated with a Buy at Alliance Global Partners
HOOK Hookipa Pharma
$2.94 /

+ (+0.00%)

11/12/21 Morgan Stanley
Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update
11/12/21 Morgan Stanley
Hookipa Pharma downgraded to Equal Weight from Overweight at Morgan Stanley
11/11/21 H.C. Wainwright
Hookipa Pharma price target lowered to $15 from $21 at H.C. Wainwright
11/10/21 JMP Securities
Hookipa Pharma price target lowered to $11 from $25 at JMP Securities
INBX Inhibrx
$36.50 /

-0.49 (-1.32%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
IOVA Iovance Biotherapeutics
$16.93 /

+0.37 (+2.23%)

12/06/21 Cowen
Iovance Biotherapeutics assumed with an Outperform at Cowen
11/15/21 Oppenheimer
Iovance price target lowered to $31 from $38 at Oppenheimer
11/05/21 H.C. Wainwright
Iovance Biotherapeutics price target lowered to $43 from $46 at H.C. Wainwright
11/05/21 Piper Sandler
Iovance Biotherapeutics price target raised to $20 from $18 at Piper Sandler
KURA Kura Oncology
$12.41 /

-0.05 (-0.40%)

11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
11/24/21 H.C. Wainwright
Kura Oncology price target lowered to $32 from $43 at H.C. Wainwright
05/04/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
04/26/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
MGN Mines Management
$1.13 /

+ (+0.00%)

MOR MorphoSys
$9.07 /

-0.39 (-4.12%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NXTC NextCure
$5.84 /

+0.1 (+1.74%)

11/05/21 Piper Sandler
NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler
08/08/21 Piper Sandler
NextCure price target lowered to $21 from $26 at Piper Sandler
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
PTGX Protagonist Therapeutics
$32.77 /

+0.43 (+1.33%)

11/15/21 JMP Securities
Protagonist Therapeutics price target raised to $70 from $60 at JMP Securities
11/04/21 Piper Sandler
Piper 'pleasantly surprised' by Protagonist Therapeutics' ASH abstracts
10/13/21 JMP Securities
Protagonist Therapeutics price target raised to $60 from $47 at JMP Securities
10/12/21 JPMorgan
JPMorgan upgrades Protagonist after 'rapid' clinical hold removal
PRTA Prothena
$44.06 /

-2.565 (-5.50%)

11/19/21 JMP Securities
Prothena initiated with an Outperform at JMP Securities
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
SYRS Syros Pharmaceuticals
$3.96 /

+0.39 (+10.92%)

09/27/21 Roth Capital
Veteran Chee coming aboard a positive for Syros, says Roth Capital
09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
VOR Vor Biopharma
$13.15 /

+0.5 (+3.95%)

12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
12/01/21 Oppenheimer
Vor Biopharma initiated with an Outperform at Oppenheimer
10/19/21 JMP Securities
Vor Biopharma initiated with an Outperform at JMP Securities
VOR Vor Biopharma
$13.15 /

+0.5 (+3.95%)

SYRS Syros Pharmaceuticals
$3.96 /

+0.39 (+10.92%)

SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

PTGX Protagonist Therapeutics
$32.77 /

+0.43 (+1.33%)

PRTA Prothena
$44.06 /

-2.565 (-5.50%)

NXTC NextCure
$5.84 /

+0.1 (+1.74%)

MOR MorphoSys
$9.07 /

-0.39 (-4.12%)

KURA Kura Oncology
$12.41 /

-0.05 (-0.40%)

IOVA Iovance Biotherapeutics
$16.93 /

+0.37 (+2.23%)

INBX Inhibrx
$36.50 /

-0.49 (-1.32%)

HOOK Hookipa Pharma
$2.94 /

+ (+0.00%)

GMDA Gamida Cell
$2.34 /

-0.015 (-0.64%)

EFTR eFfector Therapeutics
$7.44 /

+1.7 (+29.62%)

DCPH Deciphera
$8.03 /

+0.03 (+0.38%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

CUE Cue Biopharma
$10.94 /

-0.45 (-3.95%)

CTIC CTI BioPharma
$1.68 /

+0.075 (+4.69%)

CLLS Cellectis
$8.08 /

-0.18 (-2.18%)

CGEN Compugen
$4.20 /

+0.03 (+0.72%)

BPMC Blueprint Medicines
$95.36 /

+1.105 (+1.17%)

BCYC Bicycle Therapeutics
$50.35 /

-2.24 (-4.26%)

BCRX BioCryst
$11.18 /

-0.275 (-2.40%)

BCAB BioAtla
$22.46 /

+0.105 (+0.47%)

ALLO Allogene Therapeutics
$17.19 /

-0.45 (-2.55%)

  • 13
    Oct
  • 11
    Aug
  • 16
    Jun
  • 01
    Apr
  • 24
    Mar
  • 05
    Feb
  • 28
    Jan
  • 20
    Jan
  • 16
    Dec
  • 16
    Dec
  • 11
    Dec
  • 09
    Dec
  • 09
    Dec
SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

CGEN Compugen
$4.20 /

+0.03 (+0.72%)

SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

PTGX Protagonist Therapeutics
$32.77 /

+0.43 (+1.33%)

PRTA Prothena
$44.06 /

-2.565 (-5.50%)

MOR MorphoSys
$9.07 /

-0.39 (-4.12%)

KURA Kura Oncology
$12.41 /

-0.05 (-0.40%)

IOVA Iovance Biotherapeutics
$16.93 /

+0.37 (+2.23%)

DCPH Deciphera
$8.03 /

+0.03 (+0.38%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

CTIC CTI BioPharma
$1.68 /

+0.075 (+4.69%)

CGEN Compugen
$4.20 /

+0.03 (+0.72%)

BCYC Bicycle Therapeutics
$50.35 /

-2.24 (-4.26%)

BCRX BioCryst
$11.18 /

-0.275 (-2.40%)

ALLO Allogene Therapeutics
$17.19 /

-0.45 (-2.55%)

SPPI Spectrum
$1.37 /

-0.005 (-0.36%)

PTGX Protagonist Therapeutics
$32.77 /

+0.43 (+1.33%)

IOVA Iovance Biotherapeutics
$16.93 /

+0.37 (+2.23%)

INBX Inhibrx
$36.50 /

-0.49 (-1.32%)

CVAC CureVac
$40.76 /

-2.91 (-6.66%)

BCYC Bicycle Therapeutics
$50.35 /

-2.24 (-4.26%)

BCRX BioCryst
$11.18 /

-0.275 (-2.40%)

BCAB BioAtla
$22.46 /

+0.105 (+0.47%)

ALLO Allogene Therapeutics
$17.19 /

-0.45 (-2.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.